For the quarter ending 2025-09-30, CALC had -$448K decrease in cash & cash equivalents over the period. -$4,786K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,804 | -10,998 |
| Stock-based compensation expense | 625 | 1,724 |
| Depreciation | 12 | 29 |
| Change in the fair value of warrant liability | 1,600 | -1,777 |
| Change in the fair value of promissory notes | 400 | -423 |
| Promissory note issuance costs | -1 | -335 |
| Transaction costs associated with warrants | 0 | 0 |
| Accretion of discount on short-term investment | 89 | 218 |
| Prepaid expenses and other current and non-current assets | -292 | 11 |
| Accounts payable | -796 | -88 |
| Accrued expenses and other liabilities | 981 | -121 |
| Net cash used in operating activities | -4,778 | -11,548 |
| Purchase of investments | 1,480 | 13,940 |
| Maturity of investments | 5,000 | 12,845 |
| Purchases of property and equipment | 8 | 14 |
| Net cash provided by investing activities | 3,512 | -1,109 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 8 |
| Proceeds from exercise of stock options | 25 | 0 |
| Proceeds from issuance of promissory note payable, net | 0 | 9,664 |
| Proceeds from issuance of common stock from atm facility, net of issuance costs | 793 | 968 |
| Net cash provided by financing activities | 818 | 10,640 |
| Net (decrease) increase in cash and cash equivalents | -448 | -2,017 |
| Cash and cash equivalents at beginning of period | 7,935 | - |
| Cash and cash equivalents at end of period | 5,470 | - |
CalciMedica, Inc. (CALC)
CalciMedica, Inc. (CALC)